|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CPXM2 |
Gene summary for CPXM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CPXM2 | Gene ID | 119587 |
| Gene name | carboxypeptidase X, M14 family member 2 | |
| Gene Alias | CPX2 | |
| Cytomap | 10q26.13 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q8N436 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 119587 | CPXM2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 2.65e-12 | 1.33e+00 | 0.0131 |
| 119587 | CPXM2 | A008-E-015 | Human | Colorectum | FAP | 5.77e-03 | 2.58e-01 | 0.0177 |
| 119587 | CPXM2 | P2T-E | Human | Esophagus | ESCC | 6.44e-05 | 1.62e-01 | 0.1177 |
| 119587 | CPXM2 | P4T-E | Human | Esophagus | ESCC | 1.05e-10 | 1.67e-01 | 0.1323 |
| 119587 | CPXM2 | P15T-E | Human | Esophagus | ESCC | 4.63e-03 | 8.85e-02 | 0.1149 |
| 119587 | CPXM2 | P16T-E | Human | Esophagus | ESCC | 1.24e-51 | 8.80e-01 | 0.1153 |
| 119587 | CPXM2 | P26T-E | Human | Esophagus | ESCC | 2.15e-14 | 4.36e-01 | 0.1276 |
| 119587 | CPXM2 | P27T-E | Human | Esophagus | ESCC | 5.12e-47 | 7.66e-01 | 0.1055 |
| 119587 | CPXM2 | P30T-E | Human | Esophagus | ESCC | 6.29e-12 | 4.10e-01 | 0.137 |
| 119587 | CPXM2 | P47T-E | Human | Esophagus | ESCC | 4.38e-02 | 4.18e-02 | 0.1067 |
| 119587 | CPXM2 | P48T-E | Human | Esophagus | ESCC | 4.77e-05 | 2.39e-01 | 0.0959 |
| 119587 | CPXM2 | P57T-E | Human | Esophagus | ESCC | 8.09e-05 | 2.74e-01 | 0.0926 |
| 119587 | CPXM2 | P74T-E | Human | Esophagus | ESCC | 3.51e-13 | 4.01e-01 | 0.1479 |
| 119587 | CPXM2 | P76T-E | Human | Esophagus | ESCC | 1.07e-15 | 3.44e-01 | 0.1207 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00516041 | Colorectum | SER | protein maturation | 73/2897 | 294/18723 | 1.82e-05 | 5.38e-04 | 73 |
| GO:00164851 | Colorectum | SER | protein processing | 55/2897 | 225/18723 | 2.84e-04 | 4.67e-03 | 55 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CPXM2 | SNV | Missense_Mutation | c.1512G>C | p.Trp504Cys | p.W504C | Q8N436 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CPXM2 | SNV | Missense_Mutation | rs138679076 | c.1987N>A | p.Val663Ile | p.V663I | Q8N436 | protein_coding | tolerated(0.08) | possibly_damaging(0.832) | TCGA-AR-A24O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| CPXM2 | SNV | Missense_Mutation | rs778892334 | c.1678C>T | p.Arg560Cys | p.R560C | Q8N436 | protein_coding | tolerated(0.17) | possibly_damaging(0.901) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| CPXM2 | SNV | Missense_Mutation | rs529727115 | c.1697N>A | p.Arg566Gln | p.R566Q | Q8N436 | protein_coding | tolerated(0.3) | possibly_damaging(0.545) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CPXM2 | SNV | Missense_Mutation | c.1041N>A | p.Ser347Arg | p.S347R | Q8N436 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR | |
| CPXM2 | SNV | Missense_Mutation | novel | c.356C>T | p.Ala119Val | p.A119V | Q8N436 | protein_coding | tolerated(0.22) | probably_damaging(0.968) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CPXM2 | insertion | Frame_Shift_Ins | novel | c.1482_1483insAAAGGTT | p.Ala495LysfsTer122 | p.A495Kfs*122 | Q8N436 | protein_coding | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| CPXM2 | insertion | Nonsense_Mutation | novel | c.1480_1481insCCCGTTGCTGATGACGTG | p.Thr493_Val494insAlaArgCysTerTerArg | p.T493_V494insARC**R | Q8N436 | protein_coding | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| CPXM2 | deletion | Frame_Shift_Del | novel | c.482delT | p.Leu161ArgfsTer42 | p.L161Rfs*42 | Q8N436 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CPXM2 | SNV | Missense_Mutation | novel | c.2063T>G | p.Val688Gly | p.V688G | Q8N436 | protein_coding | tolerated(0.29) | benign(0.158) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |